

# Geralyn Ritter

## Organon Head of External Affairs and ESG

Geralyn Ritter is Head of External Affairs and ESG for Organon. She is focused on upholding Organon's vision and representing our values in the world by guiding and shaping how the company interacts with key stakeholders and the environment.

Geralyn joins Organon from Merck, where she spent 12 years, most recently serving as Corporate Secretary leading shareholder engagement, governance and ESG. Previously, she served as Head of Global Public Policy and Corporate Responsibility, where she was the President of the Merck Foundation and led the creation of Merck for Mothers, a global initiative to end maternal mortality. Previously, Geralyn worked at PhRMA, the Office of the U.S. Trade Representative and at the law firm of Covington & Burling.

A survivor of traumatic injury, Geralyn is a passionate advocate, frequent speaker and an author on resilience and trauma recovery. She co-chairs the Patient and Family Advisory Council at Penn Presbyterian Medical Center and is a board member of Sanford School of Public Policy at Duke University, Business for Social Responsibility, Power to Decide, and Domus Pacis Family Respite, a Colorado-based non-profit that supports patients and families facing terminally ill cancer.

Geralyn received a bachelor's degree from Duke University, a master's degree from the Johns Hopkins School of Advanced International Studies and her J.D. from the Stanford University School of Law.



---

**About Organon** Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. It has a portfolio of more than 60 medicines and products that help address a spectrum of conditions women face. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon's products produce strong cash flows that will support investments in future growth opportunities in women's health, including business development. In addition, Organon is pursuing opportunities to partner with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey. For more information, visit [organon.com](https://www.organon.com) and connect with us on LinkedIn, Instagram and Twitter.